1311275-35-0

Basic information

• Product Name: 6-Bromo-2,4-dichlorothieno[3,2-d]pyrimidine
• Synonyms: 6-Bromo-2,4-dichlorothieno[3,2-d]pyrimidine
• CAS NO: 1311275-35-0
• Molecular Formula: C₆HBrCl₂N₂S
• Molecular Weight: 283.96054
• Mol File: 1311275-35-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 2.034±0.06 g/cm3(Predicted)
• PKA: -1.45±0.40(Predicted)
• CAS DataBase Reference: 6-Bromo-2,4-dichlorothieno[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2,4-dichlorothieno[3,2-d]pyrimidine(1311275-35-0)
• EPA Substance Registry System: 6-Bromo-2,4-dichlorothieno[3,2-d]pyrimidine(1311275-35-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 1311275-35-0(Hazardous Substances Data)

Usage

General Description

6-bromo-2,4-dichlorothieno[3,2-d]pyrimidine is a chemical compound with the molecular formula C6H2BrCl2N2S. It is a heterocyclic organic compound that contains two chlorine atoms, one bromine atom, one nitrogen atom, and one sulfur atom. 6-bromo-2,4-dichlorothieno[3,2-d]pyrimidine is a thienopyrimidine derivative and is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. It has potential applications in the field of medicinal chemistry and drug discovery due to its ability to interact with biological targets and modulate their activity. Additionally, it has been studied for its potential use as a pesticide or herbicide.

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 860354-58-1 methyl 5-bromo-3-({[(trichloroacetyl)amino]carbonyl}amino)thiophene-2-carboxylate 
• 860354-59-2 3-[(aminocarbonyl)amino]-5-bromo-2-thiophenecarboxylic acid methyl ester 
• 1388027-23-3 6-bromothieno[3,2-d]pyrimidine-2,4-diol 
• 860354-57-0 methyl 3-({[(trichloroacetyl)amino]carbonyl}amino)thiophene-2-carboxylate 
• 107818-55-3 3-amino-5-bromo-thiophene-2-carboxylic acid methyl ester 

Relevant articles and documents

Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool

Long-acting dipeptidyl peptidase IV inhibitors have emerged as promising molecules for interventions for type 2 diabetes. Once weekly dosing brings greater patient compliance and more stable glycemic control. Starting from our previous highly potent compound with a thienoprimidine scaffold, which is unfortunately severely hit by hepatic biotransformation, a lead compound was rapidly generated by drawing on the experience of our previously discovered long-acting compounds with pyrrolopyrimidine scaffold. With the aid of an in silico biotransformation prediction tool, (R)-2-((2-(3-aminopiperidin-1-yl)-4-oxo-6-(pyridin-3-yl)thieno[3,2-d]pyrimidin-3(4H)-yl)methyl)-4-fluorobenzonitrile was eventually generated and determined to have high potency, a fine pharmacokinetic profile, and a long-acting in vivo efficacy.

2,4-Diaminothienopyrimidines as orally active antimalarial agents

A novel series of 2,4-diaminothienopyrimidines with potential as antimalarials was identified from whole-cell high-throughput screening of a SoftFocus ion channel library. Synthesis and structure-activity relationship studies identified compounds with potent antiplasmodial activity and low in vitro cytotoxicity. Several of these analogues exhibited in vivo activity in the Plasmodium berghei mouse model when administered orally. However, inhibition of the hERG potassium channel was identified as a liability for this series.